Zothanpari Ralte, (2020) A Prospective Comparative study of Tamoxifen Versus Standard treatment response in Fibrocystic Disease of the Breast in Tertiary Health Care. Masters thesis, Stanley Medical College, Chennai.
|
Text
220100220zothanpari_ralte.pdf Download (4MB) | Preview |
Abstract
INTRODUCTION: World Health Organisation have enumerated Tamoxifen as a necessary ingredient in the treatment protocol of breast cancer. Since a quarter of a century, it is been used as the gold standard endocrine method of treating oestrogen-receptor-positive breast cancer, irrespective of staging. AIMS AND OBJECTIVES: To assess the effectiveness of Tamoxifen in fibrocystic disease (benign breast disease) of the breast. METHODS: It was a Comparative Prospective Single Center Study in the Department of General surgery, Government Stanley Medical College from September-2018 to September- 2019 among Patients who are diagnosed with fibrocystic breast disease are recruited from the surgery department. Based on the lottery method, consecutive patients are randomised into two groups; Each group contains 20 patients with a total sample size of 40. RESULTS: The mean age of the Tamoxifen group is 35.15 years with a standard deviation of 4.79 years with a median of 37 years ranging from 25 years to 40 years. The mean age of the Primrose group is 31.20 years with a standard deviation of 3.98 years with a median of 30 years ranging from 26 years to 39 years. In the Tamoxifen group, the disease was present on the right side in eight patients and on the left side in twelve patients. In the Evening Primrose group, the disease was present on the right side in seven patients and on the left side in thirteen patients. All lesions were cystic in nature Majority (n=22) of the patients had grade 3 pain with 10 patients in the Evening Primrose group and 12 patients in the Tamoxifen group. The two groups are comparable and does not differ significantly in the grading of pain. Both the Groups received treatment for three months. The Cardiff Breast Pain Score was comparable between the two groups with no significant differences. The reduction in size of the lump was better in Tamoxifen group with 8 of them showing reduction whereas in the Evening Primrose group only three of them had a reduction in the size of the lump. The difference is statistically significant. Out of 20 patients in the Tamoxifen group, only two of them had side effects while five of them had side effects in the Evening Primrose group. Out of the two patients in the Tamoxifen group with side effects, one of them had Hot flashes while the other one had Menorrhagia. Whereas in the Primrose group, three of them had headache and two of them had diarrhea. CONCLUSION: The outcome was better in the group that was treated with Tamoxifen as compared to the treatment with evening Primrose group.
| Item Type: | Thesis (Masters) |
|---|---|
| Additional Information: | 221711072 |
| Uncontrolled Keywords: | Tamoxifen, Standard treatment response, Fibrocystic Disease, Breast,Tertiary Health Care, Prospective Comparative study. |
| Subjects: | MEDICAL > General Surgery |
| Depositing User: | Subramani R |
| Date Deposited: | 09 Feb 2021 02:36 |
| Last Modified: | 09 Feb 2021 02:36 |
| URI: | http://repository-tnmgrmu.ac.in/id/eprint/13959 |
Actions (login required)
 |
View Item |
